Fenwick represented DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, in its $60 million Series C-1 financing.
The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital. Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
DiCE Molecules will use the funds to support advancement of its preclinical IL-17 antagonist franchise into clinical development, advancement of preclinical α4ß7 and αVß1/αVß6 integrin programs, pipeline expansion and other general corporate purposes. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by corporate partner Matt Rossiter and included corporate associates Myles Gutenkunst and Riddhi Adhikari.